The emerging role of glucagon-like peptide 1 in binge eating
Journal of Endocrinology · 17.04.2024 · 262 (1)
DOI: 10.1530/joe-23-0405 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Endocrinology, erschienen am 17.04.2024. Verfasst von Katherine N Balantekin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Exercise and Nutrition Sciences, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Binge eating is a central component of two clinical eating disorders: binge eating disorder and bulimia nervosa. However, the large treatment gap highlights the need to identify other strategies to decrease binge eating. Novel pharmacotherapies may be one such approach. Glucagon-like peptide-1 (GLP-1) is an intestinal and brain-derived neuroendocrine signal with a critical role in promoting glycemic control through its incretin effect. Additionally, the energy balance effects of GLP-1 are well-established; activation of the GLP-1 receptor (GLP-1R) reduces food intake and body weight. Aligned with these beneficial metabolic effects, there are GLP-1R agonists that are currently used for the treatment of diabetes and obesity. A growing body of literature suggests that GLP-1 may also play an important role in binge eating. Dysregulation of the endogenous GLP-1 system is associated with binge eating in non-human animal models, and GLP-1R agonists may be a promising approach to suppress the overconsumption that occurs during binge eating. Here, we briefly discuss the role of GLP-1 in normal energy intake and reward and then review the emerging evidence suggesting that disruptions to GLP-1 signaling are associated with binge eating. We also consider the potential utility of GLP-1-based pharmacotherapies for reducing binge eating behavior.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Exercise and Nutrition Sciences, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York, USA.
- Center for Ingestive Behavior Research, University at Buffalo, Buffalo, New York, USA.
ORCID-Profile: Elizabeth G Mietlicki-Baase
Förderung
- NIDDK NIH HHS
Zitieren
APA
Balantekin, K. N., Kretz, M. J., & Mietlicki-Baase, E. G. (2024). The emerging role of glucagon-like peptide 1 in binge eating. Journal of Endocrinology, 262(1). https://doi.org/10.1530/joe-23-0405
Vancouver
Balantekin KN, Kretz MJ, Mietlicki-Baase EG. The emerging role of glucagon-like peptide 1 in binge eating. Journal of Endocrinology. 2024;262(1). doi:10.1530/joe-23-0405
BibTeX
@article{Balantekin2024,
author = {Balantekin, Katherine N and Kretz, Martin J and Mietlicki-Baase, Elizabeth G},
title = {The emerging role of glucagon-like peptide 1 in binge eating},
journal = {Journal of Endocrinology},
year = {2024},
volume = {262},
number = {1},
doi = {10.1530/joe-23-0405}
}
EUVIMED